Financial Markets
Real Estate
Local listed Company
Overseas-listed Company
Foreign Company
Industrial Parks

Company - Overseas
 Search News  Or
KKR to inject US$65 mln into China Cord Blood

Apr. 13, 2012 (China Knowledge) - China Cord Blood Corp (CCBC), the country’s largest operator of services for umbilical cord blood that is rich in stem cells, announced yesterday that U.S. private-equity Kohlberg Kravis Roberts & Co L.P. (KKR) has agreed to invest US$65 million in the Chinese company, sources reported.

The capital injection will be completed through KKR China Growth Fund L.P., a China-focus investment fund managed by KKR.

KKR has hired Citigroup as its financial advisor for the deal.

CCBC, listed on the New York Stock Exchange in 2009, is a unit of Golden Meditech Holdings Ltd<0801> and is the first licensed cord blood banking operator in the country, offering collection, testing, processing and storage services. The company operates the country's largest cord blood banking network covering 180 million people and with 1.9 million new births per year.

Add this     
Copyright © "2015"

Send feedback or comments to:

For more news, financial weekly reports, business guides to China, Market Research Reports and other premium information, subscribe to China Knowledge today

To access our page on Bloomberg, type CKFI (GO)

 Our Professional Services


 News Archive
About Us | CSR | Media Center | E-Newsletter | E-Store | Contact Us | Feedback | Sitemap | Privacy Policy | Terms of Use  

           Copyright © 2014 China Knowledge Online. All Rights Reserved